Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Apr 1;33(10):1151-6.
doi: 10.1200/JCO.2014.58.2973. Epub 2015 Mar 2.

Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT

Laurence Klotz  1 , Chris O'Callaghan  2 , Keyue Ding  2 , Paul Toren  2 , David Dearnaley  2 , Celestia S Higano  2 , Eric Horwitz  2 , Shawn Malone  2 , Larry Goldenberg  2 , Mary Gospodarowicz  2 , Juanita M Crook  2
Affiliations
Randomized Controlled Trial

Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT

Laurence Klotz et al. J Clin Oncol. .

Erratum in

  • ERRATUM.
    [No authors listed] [No authors listed] J Clin Oncol. 2016 Jun 1;34(16):1965. doi: 10.1200/JCO.2016.68.1882. J Clin Oncol. 2016. PMID: 27217531 Free PMC article. No abstract available.

Abstract

Purpose: Three small retrospective studies have suggested that patients undergoing continuous androgen deprivation (CAD) have superior survival and time to progression if lower castrate levels of testosterone (< 0.7 nmol/L) are achieved. Evidence from prospective large studies has been lacking.

Patients and methods: The PR-7 study randomly assigned patients experiencing biochemical failure after radiation therapy or surgery plus radiation therapy to CAD or intermittent androgen deprivation. The relationship between testosterone levels in the first year and cause-specific survival (CSS) and time to androgen-independent progression in men in the CAD arm was evaluated using Cox regression.

Results: There was a significant difference in CSS (P = .015) and time to hormone resistance (P = .02) among those who had first-year minimum nadir testosterone ≤ 0.7, > 0.7 to ≤ 1.7, and ≥ 1.7 nmol/L. Patients with first-year nadir testosterone consistently > 0.7 nmol/L had significantly higher risks of dying as a result of disease (0.7 to 1.7 nmol/L: hazard ratio [HR], 2.08; 95% CI, 1.28 to 3.38; > 1.7 nmol/L: HR, 2.93; 95% CI, 0.70 to 12.30) and developing hormone resistance (0.7 to 1.7 nmol/L: HR, 1.62; 95% CI, 1.20 to 2.18; ≥ 1.7 nmol/L: HR, 1.90; 95% CI, 0.77 to 4.70). Maximum testosterone ≥ 1.7 nmol/L predicted for a higher risk of dying as a result of disease (P = .02).

Conclusion: Low nadir serum testosterone (ie, < 0.7 mmol/L) within the first year of androgen-deprivation therapy correlates with improved CSS and duration of response to androgen deprivation in men being treated for biochemical failure undergoing CAD.

Trial registration: ClinicalTrials.gov NCT00003653.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest are found in the article online at www.jco.org. Author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
PR-7 CONSORT diagram. ADT, androgen-deprivation therapy; CAD, continuous androgen deprivation; CRPC, castration-resistant prostate cancer; PSA, prostate-specific antigen.
Fig 2.
Fig 2.
Time to castration-resistant prostate cancer according to (A) median, (B) nadir, and (C) maximum first-year testosterone (testo) levels. HR, hazard ratio.
Fig 3.
Fig 3.
Cause-specific survival according to (A) median, (B) nadir, and (C) maximum first-year testosterone (testo) levels. HR, hazard ratio.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate—1941. J Urol. 2002;168:9–12. - PubMed
    1. Morote J, Planas J, Salvador C, et al. Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy. BJU Int. 2009;103:332–335. - PubMed
    1. Pickles T, Hamm J, Morris WJ, et al. Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: Does it happen and does it matter? BJU Int. 2012;110:E500–E507. - PubMed
    1. Morote J, Orsola A, Planas J, et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol. 2007;178:1290–1295. - PubMed
    1. Perachino M, Cavalli V, Bravi F. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: Prognostic significance? BJU Int. 2010;105:648–645. - PubMed

Publication types

MeSH terms

Associated data